Research Products and Multi-Vial Collections
Research Summary
Reta-GLP3-Rta is classified as a triple incretin receptor agonist peptide investigated for its interaction with multiple endocrine receptor systems involved in metabolic signaling pathways.
Research investigations commonly evaluate:
- GLP-1 receptor signaling
• GIP receptor interaction
• Glucagon receptor activation
• Multi-receptor incretin pathway modulation
• Metabolic regulatory pathway research
Triple agonist peptides represent an emerging class of investigational compounds studied for complex endocrine pathway interactions across metabolic research models.
Available Vial Options
30mg or 60mg Lyophilized Vial
All vial configurations meet identical ≥99% purity standards and undergo third-party analytical verification.
Stack Composition
Technical Specifications
| Product Name | GLP3-Rta |
| Functional Category | Triple incretin receptor agonist |
| Target Receptors | GLP-1 receptor (GLP-1R) GIP receptor (GIPR) Glucagon receptor (GCGR) |
| Purity | ≥99% (HPLC verified) |
| Form | Lyophilized powder |
| Testing Location | Tested and verified in the USA |
| Testing | Third-party verified |
| Intended Use | Laboratory research only |
Research Compound Profile
| Attribute | Description |
|---|---|
| Compound Type | Triple incretin receptor agonist |
| Molecular Class | Synthetic peptide analog |
| Target Receptors | GLP-1R / GIPR / GCGR |
| Research Category | Metabolic signaling |
| Form | Lyophilized powder |
| Purity | ≥99% |
Mechanism of Action
In laboratory models, Reta-GLP3-Rta is examined for simultaneous activation of three incretin-related receptor systems, providing a broader receptor engagement profile than dual-agonist peptides.
Research investigations explore:
- GLP-1 receptor signaling cascades
• GIP-mediated endocrine signaling
• Glucagon receptor metabolic pathway activation
• Integrated hormonal signaling networks
• Multi-pathway metabolic regulation models
The triple receptor profile differentiates Reta-GLP3-Rta from single-pathway and dual-pathway incretin analogs studied in metabolic research environments.
Areas of Scientific Investigation
- Metabolic endocrine signaling
• Multi-receptor hormone pathway interaction
• Energy homeostasis research models
• Endocrine receptor modulation
• Glucose metabolism signaling studies
All references reflect laboratory research environments only.
Storage & Handling
- Store at 2–8°C
• Protect from moisture and light
• Maintain sterile laboratory conditions
• Follow institutional research protocols for reconstitution
Quality & Verification
PeptideBlend research peptides are:
- Tested and verified in the United States
• Third-party verified for identity and purity
• Confirmed ≥99% purity via HPLC analysis
Certificates of Analysis available upon request.
Frequently Asked Questions
What is Reta-GLP3-Rta?
A triple incretin receptor agonist peptide studied for its interaction with GLP-1, GIP, and glucagon receptors.
What receptors does Reta-GLP3-Rta target?
GLP-1R, GIPR, and GCGR.
What form is Reta-GLP3-Rta supplied in?
Lyophilized powder for laboratory research reconstitution.
Is Reta-GLP3-Rta for human use?
No. This compound is supplied strictly for laboratory research.
Scientific Literature Context
Research on triple incretin receptor agonists explores multi-pathway endocrine signaling and metabolic hormone interactions across controlled laboratory environments.
Research Use Disclaimer
This product is intended strictly for laboratory research and analytical purposes only.
Not for human consumption.